Alto Neuroscience (NYSE:ANRO) Releases Earnings Results, Beats Estimates By $0.09 EPS

Alto Neuroscience (NYSE:ANRO) issued its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09, Zacks reports.

Alto Neuroscience Stock Performance

Shares of Alto Neuroscience stock traded down $0.11 during trading hours on Thursday, hitting $2.69. The company’s stock had a trading volume of 207,871 shares, compared to its average volume of 359,519. The business has a fifty day moving average of $3.70 and a 200 day moving average of $6.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. Alto Neuroscience has a 1-year low of $2.64 and a 1-year high of $18.35.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.